Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2007
12/20/2007US20070293521 inhibitors of immunoglobulin E or G receptor signaling cascades; Syk kinase inhibitors; use as antiallergic, antiinflammatory agents
12/20/2007US20070293520 2,4-pyrimidinediamine compounds and their uses
12/20/2007US20070293519 Analogs of thalidomide as potential angiogenesis inhibitors
12/20/2007US20070293518 Prolonged improvement of renal function comprising infrequent administration of an aa1ra
12/20/2007US20070293517 Derivatives Of Chemotherapeutic Agents With A Formaldehyde Releasing Moiety
12/20/2007US20070293516 Kinase antagonists
12/20/2007US20070293515 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists
12/20/2007US20070293513 Cristalline and amorphous form of a triazolo (4,5-d) pyridimine compound
12/20/2007US20070293512 2-[4-(4-Chlorophenylthio)-3-nitrophenyl]-4-mercaptothiazolo[5,4-d]pyrimidine; hyperuricemia; gout
12/20/2007US20070293511 Crf Receptor Antagonists and Methods
12/20/2007US20070293509 treating eating disorders, obesity, type II diabetes, and substance abuse and/or addiction (including alcohol dependency and nicotine dependency); 6-(4-chloro-phenyl)-5-[methyl-(3-methyl-butyl)-amino]-pyrazine-2-carboxylic acid ((R)-2-cyclopropyl-2-hydroxy-propyl)-amide
12/20/2007US20070293508 Crf Receptor Antagonists and Methods Relating Thereto
12/20/2007US20070293507 Pyrazole Kinase Modulators And Methods Of Use
12/20/2007US20070293506 Combination preparations comprising bifeprunox and a dopamine agonist
12/20/2007US20070293505 Combination preparations comprising slv308 and a dopamine agonist
12/20/2007US20070293504 N-phenyl-2-pyrimidine-amine derivatives
12/20/2007US20070293503 Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
12/20/2007US20070293502 Diarylmethyl Piperazine Derivatives, Preparations Thereof and Uses Thereof
12/20/2007US20070293501 Thioalkeneamides as Transketolase Inhibitors
12/20/2007US20070293500 Quinazoline derivatives as medicaments
12/20/2007US20070293499 Intracellular Kinase Inhibitors
12/20/2007US20070293498 used for the treatment of cachexia and other weight loss disorders, such as those resulting from cancer, HIV, old age and anorexia nervosa
12/20/2007US20070293497 2,3,4,6-Substituted Pyridyl Derivative Compounds Useful As Beta-Secretase Inhibitors For The Treatment Of Alzheimer's Disease
12/20/2007US20070293496 Nitrogen containing heterocyclic compounds and medicines containing the same
12/20/2007US20070293495 to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine
12/20/2007US20070293494 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines
12/20/2007US20070293493 Oxazolidinone antibiotics and derivatives thereof
12/20/2007US20070293492 Quinoline Tachykinin Receptor Antagonists
12/20/2007US20070293491 Indazole compounds and methods for inhibition of cdc7
12/20/2007US20070293490 Quinazoline Derivatives
12/20/2007US20070293489 Substituted Pyrazolopyrimidines
12/20/2007US20070293488 tyrosine kinase inhibitors such as 1-(2-fluoro-5-trifluoromethylphenyl)-3-[4-(5-oxo-5,8-dihydropyrido[2,3-d]pyrimidin-4-ylamino)phenyl]urea, used as antitumor or anticarcinogenic agents or for the treatment of psoriasis, arthritis, retinopathy or dermatitis
12/20/2007US20070293487 Benzothiazole- and benzooxazole-4,7-dione, derivatives and their use as cdc25 phosphate inhibitors
12/20/2007US20070293486 Alpha-Keto Carbonyl Calpain Inhibitors
12/20/2007US20070293485 Drug administration methods
12/20/2007US20070293484 Thiophene Heteroaryl Amines
12/20/2007US20070293483 Acetyl 2-hydroxy-1, 3-diaminoalkanes
12/20/2007US20070293482 Process for Preparing Benzodiazepines
12/20/2007US20070293481 Treating obesity with muscarinic receptor m1 antagonists
12/20/2007US20070293480 Treating psychological conditions using muscarinic receptor m1 antagonists
12/20/2007US20070293479 Olanzapine pharmaceutical composition
12/20/2007US20070293478 such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses
12/20/2007US20070293477 Novel Compounds
12/20/2007US20070293476 Co-therapy for the treatment of epilepsy and related disorders
12/20/2007US20070293475 Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
12/20/2007US20070293474 Combination of a DPP IV inhibitor and a cardiovascular compound
12/20/2007US20070293473 Use of acylaminoalkenylene-amide derivatives in functional motility disorders of the viscera
12/20/2007US20070293472 Novel 14 and 15 Membered Ring Compounds
12/20/2007US20070293471 by reaction of 11-piperazinyldibenzo[b,f][1,4]-thiazepine with 2-(2-chloroethoxy)ethanol in presence of organic or inorganic base (such as sodium carbonate, sodium bicarbonate, potassium carbonate) under neat or aqueous condition, in presence of phase transfer catalyst (tetrabutylammonium bromide)
12/20/2007US20070293470 Carboxamide Spirolactam Cgrp Receptor Antagonists
12/20/2007US20070293469 Compositions and methods for the treatment and prevention of disease
12/20/2007US20070293468 Reacting indazolium hydrochloride with Sodium tetrachlorobisindazoleruthenate(III) to form trans-Indazolium [tetrachlorobisindazoleruthenate(III)] (KP1019), and sodium chloride; both highly effective and water soluble; bioavailability; cancer treatment
12/20/2007US20070293467 Demethyl-Cantharidin Platinum Complex Isomers and Their Use
12/20/2007US20070293466 Antimicrobial Chelates
12/20/2007US20070293465 Compounds for enzyme inhibition
12/20/2007US20070293464 Substituted Pyrimidine Compositions and Methods of Use
12/20/2007US20070293463 Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
12/20/2007US20070293462 Method for Inhibiting Cellular Na+-K+ ATPase Activity
12/20/2007US20070293461 Biphenyl compounds useful as muscarinic receptor antagonists
12/20/2007US20070293460 Delivery of a combination therapy for asthma and chronic obstructive pulmonary disease
12/20/2007US20070293459 Method for Inhibiting Cellular Na+-K+ ATPase Activity
12/20/2007US20070293458 Prevention of nuclear, solar, and other radiation-induced tissue damage
12/20/2007US20070293457 Boron-containing small molecules as anti-inflammatory agents
12/20/2007US20070293456 Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds
12/20/2007US20070293454 Complex Containing Mequitazine, a Cyclodextrin and an Interaction Agent
12/20/2007US20070293453 Combinatorial Methods For Inducing Cancer Cell Death
12/20/2007US20070293452 Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
12/20/2007US20070293450 Identification of ses-3 and the uses of same
12/20/2007US20070293448 Synthetic gagpol genes and their uses
12/20/2007US20070293447 Gene Therapy for Skin Disorders Using Needleless Syringes
12/20/2007US20070293446 Compositions comprising C-13 alkoxyether macrolide compounds and phenylpyrazole compounds
12/20/2007US20070293445 Stable Elsamitrucin Salts Suitable for Pharmaceutical Formulations
12/20/2007US20070293444 Novel Nucleoside Transport Inhibitors
12/20/2007US20070293443 Composition for Accelerating Calcium Absorption
12/20/2007US20070293442 Antithrombotic compound
12/20/2007US20070293441 High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
12/20/2007US20070293440 O-fused heterocycle sulfonylurea compounds with another anticonvulsant or antiepileptic agent such as carbamazepine
12/20/2007US20070293439 Methods and Compositions for Treating Hyperglycemic, Hyperlipidemic, or Hyperinsulinemic Disorders
12/20/2007US20070293436 Cytoprotective thereapeutic agents for the prevention of reperfusion injury following ischemic stroke
12/20/2007US20070293433 Methods of treating aging of skin with oligosaccharides in cosmetic or dermatological compositions that stimulate adhesion of keratinocytes to major proteins of the dermoepidermal junction and restore epidermal cohesion
12/20/2007US20070293428 Methods of treating joint pain in a subject by using an anti-angiogenic agent
12/20/2007US20070293427 Glycosaminoglycans; food complements, medicaments; joint pain, obesity; bioavailability
12/20/2007US20070293425 Mutein of a Bone Morphogenetic Protein and Use Thereof
12/20/2007US20070293423 Compounds, Methods and Formulations for the Oral Delivery of a Glucagon-Like Peptide (Glp)-1 Compound or a Melanocortin-4 Receptor (Mc4) Agonist Peptide
12/20/2007US20070292933 Inhibitors of serine proteases, particular HCV NS3-NS4A protease
12/20/2007US20070292883 Method of treating diseases with PARP inhibitors
12/20/2007US20070292545 Anti-infective agents and methods of use
12/20/2007US20070292539 Anti-inflammatory cranberry flavonol extract preparations
12/20/2007US20070292538 Formulation for hair growth
12/20/2007US20070292536 Composition and method for treating patients with high neurotransmitter levels
12/20/2007US20070292535 Strontium compositions and methods of treating arthritic and or osteoporitic conditions
12/20/2007US20070292534 Antacid and breath freshening composition
12/20/2007US20070292532 Vanadium Compounds as Inhibitors of Phosphatases
12/20/2007US20070292531 Composition for oral use and methods for application of same
12/20/2007US20070292529 Strontium compositions and methods of treating osteoporotic conditions
12/20/2007US20070292523 Dihydropyrimidine Formulations
12/20/2007US20070292519 Method of producing a nicotine medicament and a medicament made by the method
12/20/2007US20070292515 Solid dosage form containing a taste masked active agent
12/20/2007US20070292513 Pazopanib hydrochloride and synthesis, chemical intermediates, and dosage forms thereof; anticancer; colon cancer, breast cancer
12/20/2007US20070292512 Solid Oral Dosage Form Containing an Enhancer